Article: Rezzayo Proves Effective in Candidemia, Candidiasis

In a heavily pretreated patient population, rezafungin (Rezzayo, Melinta Therapeutics) was found to be a safe and effective treatment for candidemia, candidiasis and respiratory mold infection, providing support for the successful outpatient treatment of those with various fungal infections.

Rezafungin, a novel long-acting IV echinocandin, received FDA approval in 2023. The study’s lead investigator, Lucinda J. Van Anglen, PharmD, presented the results of the retrospective cohort study at ESCMID Global 2025, in Vienna.

To read the full IDSE article by Susan Kreimer, please click here!